| ETN starters (n = 45) | ADA starters (n = 45) | Effect estimate for ETN vs. ADA (95% CI) | P-value |
---|---|---|---|---|
Improvement in VAS well-being compared to baseline, median (IQR) | 2.0 (0.0 – 5.0) | 2.0 (0.0 – 4.0) | 0.89 (-0.01 – 1.78)a | 0.06 |
Decrease in active joint count compared to baseline, median (IQR) | 3 (1 – 6)b | 2 (1 – 4) | -0.36 (-1.02 – 0.30)a | 0.28 |
Adverse events, n (%) | 11 (24.4%) | 15 (34.9%)c | 0.48 (0.16 – 1.44)d | 0.19 |
Uveitis events, n (%) | 1 (2.2%) | 0 (0.0%) | - | - |